On Monday, Nektar Therapeutics (NASDAQ: NKTR) opened higher 3.51% from the last session, before settling in for the closing price of $1.14. Price fluctuations for NKTR have ranged from $0.46 to $1.93 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.42%. Company’s average yearly earnings per share was noted 49.34% at the time writing. With a float of $178.21 million, this company’s outstanding shares have now reached $184.46 million.
Let’s determine the extent of company efficiency that accounts for 137 employees. In terms of profitability, gross margin is 67.8%, operating margin of -145.96%, and the pretax margin is -180.71%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nektar Therapeutics is 3.39%, while institutional ownership is 74.37%. The most recent insider transaction that took place on Nov 19 ’24, was worth 7,863. In this transaction Chief R&D Officer of this company sold 7,785 shares at a rate of $1.01, taking the stock ownership to the 243,019 shares. Before that another transaction happened on Nov 19 ’24, when Company’s Chief Legal Officer sold 6,407 for $1.01, making the entire transaction worth $6,471. This insider now owns 218,856 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.22 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.2) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 49.34% per share during the next fiscal year.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Check out the current performance indicators for Nektar Therapeutics (NKTR). In the past quarter, the stock posted a quick ratio of 4.24. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.36.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.75 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Looking closely at Nektar Therapeutics (NASDAQ: NKTR), its last 5-days average volume was 1.52 million, which is a drop from its year-to-date volume of 1.76 million. As of the previous 9 days, the stock’s Stochastic %D was 83.14%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 37.15%, which indicates a significant decrease from 50.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.29% in the past 14 days, which was higher than the 66.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2562, while its 200-day Moving Average is $1.2471. However, in the short run, Nektar Therapeutics’s stock first resistance to watch stands at $1.2100. Second resistance stands at $1.2400. The third major resistance level sits at $1.2700. If the price goes on to break the first support level at $1.1500, it is likely to go to the next support level at $1.1200. Now, if the price goes above the second support level, the third support stands at $1.0900.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are currently 184,458K shares outstanding in the company with a market cap of 219.58 million. Presently, the company’s annual sales total 90,120 K according to its annual income of -276,060 K. Last quarter, the company’s sales amounted to 24,120 K and its income totaled -37,060 K.
